TD Private Client Wealth LLC Lowers Stock Holdings in DexCom, Inc. $DXCM

TD Private Client Wealth LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 34.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 322 shares of the medical device company’s stock after selling 171 shares during the quarter. TD Private Client Wealth LLC’s holdings in DexCom were worth $28,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DXCM. Brighton Jones LLC increased its stake in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after acquiring an additional 11,946 shares during the period. GAMMA Investing LLC grew its holdings in DexCom by 5,951.7% during the first quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company’s stock worth $34,128,000 after acquiring an additional 491,488 shares during the period. Fifth Third Wealth Advisors LLC boosted its position in shares of DexCom by 14.8% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 7,043 shares of the medical device company’s stock worth $481,000 after purchasing an additional 908 shares in the last quarter. Rhumbline Advisers grew its stake in shares of DexCom by 4.3% during the 1st quarter. Rhumbline Advisers now owns 809,803 shares of the medical device company’s stock worth $55,301,000 after purchasing an additional 33,574 shares during the period. Finally, Czech National Bank increased its holdings in shares of DexCom by 6.0% in the 1st quarter. Czech National Bank now owns 89,737 shares of the medical device company’s stock valued at $6,128,000 after purchasing an additional 5,048 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $67.29 on Wednesday. The company has a 50-day simple moving average of $77.56 and a 200-day simple moving average of $78.02. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a market cap of $26.39 billion, a PE ratio of 46.73, a price-to-earnings-growth ratio of 1.39 and a beta of 1.48. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s revenue was up 15.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $106.00 price target on shares of DexCom in a research report on Monday. Argus began coverage on DexCom in a research report on Thursday, August 21st. They set a “buy” rating and a $100.00 target price on the stock. Morgan Stanley raised their price target on DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Piper Sandler lifted their price target on DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a research note on Thursday, July 31st. Finally, UBS Group upped their price target on shares of DexCom from $105.00 to $106.00 and gave the company a “buy” rating in a report on Thursday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $99.11.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kyle Malady sold 667 shares of the company’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock worth $564,733 over the last ninety days. Company insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.